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Toll-like receptors and rheumatoid arthritis
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that ultimately leads to the progressive
destruction of cartilage and bone in numerous joints. There is mounting evidence for an important
function of innate immunity in the pathogenesis of RA. Activation of cells by microbial components and
also by endogenous molecules via Toll-like receptor (TLR) results in the production of a variety of
proinflammatory cytokines, chemokines, and destructive enzymes, some of which can characteristically
be found in RA.By immunohistochemistry we found elevated TLR2, 3, and 4 expressions in the
rheumatoid synovium. In the synovial lining layer and at sites of invasion into cartilage, RA synovial
fibroblasts (RASF) are the major cells expressing TLR2, 3, and 4. Stimulation of cultured RASF in vitro
with the TLR2 ligand bacterial lipoprotein (bLP), the TLR3 ligand poly(I-C), and the TLR4 ligand LPS
was shown to upregulate IL-6 as well as matrix metalloproteinases (MMPs) 1 and 3. These results
suggest an important role for TLR2, 3, and 4 in the activation of synovial fibroblasts in RA leading to
chronic inflammation and joint destruction.
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Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that ultimately leads to the 
progressive destruction of cartilage and bone in numerous joints. There is mounting evidence 
for an important function of innate immunity in the pathogenesis of RA. Activation of cells by 
microbial components and also by endogenous molecules via Toll-like receptors (TLR) 
results in the production of a variety of proinflammatory cytokines, chemokines and 
destructive enzymes, some of which can characteristically be found in RA.  
By immunohistochemistry we found elevated TLR2, 3 and 4 expression in the rheumatoid 
synovium. In the synovial lining layer and at sites of invasion into cartilage RA synovial 
fibroblasts (RASF) are the major cells expressing TLR2, 3 and 4. Stimulation of cultured 
RASF in vitro with the TLR2 ligand bLP, the TLR3 ligand poly(I-C) and the TLR4 ligand 
LPS was shown to upregulate IL-6 as well as matrix metalloproteinases 1 and 3. These results 
suggest an important role for TLR2 ,3 and 4 in the activation of synovial fibroblasts in RA 
leading to chronic inflammation and joint destruction. 
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Rheumatoid arthritis (RA) is a chronic inflammatory disease with progressive articular 
damage caused by inflammatory cells and synoviocytes. Cartilage RA synovial fibroblasts 
(RASF) must be considered key cells in mediating the destruction of cartilage and bone in the 
affected joints. They are mainly found in the synovial lining layer which is thickened and 
hyperplastic in RA (1). RASF are part of the innate immune system and they express pattern-
recognition receptors, such as the Toll-like receptors (TLRs), which sense certain highly 
conserved structures that are found on many different bacterial and viral products. The 
recognition of specific microbial / viral structures, such as bacterial lipoproteins (bLP, TLR2 
ligand), double stranded RNA (dsRNA, TLR3 ligand) or lipopolysaccharides (LPS, TLR4 
ligand), by TLRs results in the up-regulation of costimulatory molecules as well as in the 
induction of proinflammatory and destructive mediators. In the inflamed joints of RA patients 
endogenous TLR ligands are present. Endogenous TLR2 and 4 ligands include several heat 
shock proteins while RNA released from necrotic synovial fluid cells acts as an endogenous 
ligand for TLR3 (2, 3). Considering the important role of TLR signalling as a critical link 
between innate and adaptive immunity it has been proposed that a dysregulation in TLR 
signalling might be associated with autoimmune diseases, such as RA (4, 5).  
 
To investigate whether TLR2, 3 and 4 are expressed in RA synovial tissues we performed 
immunohistochemistry on snap frozen RA synovial tissues with commercially available 
polyclonal antibodies. As non inflammatory controls we also stained synovial tissues derived 
from osteoarthritis (OA) patients. By this technique we found TLR2, 3 and 4 proteins to be 
broadly expressed in synovial tissues derived from RA patients (6, 7). In particular, there was a 
pronounced expression in the synovial lining layer. In comparison to RA tissues, TLR2, 3 and 
4 protein expression was markedly lower in OA synovial tissues.  
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The RA synovial lining layer is composed of activated synovial fibroblasts and macrophages. 
To characterize the TLR3 expressing cells in the synovial lining layer, tissue sections were 
double stained for TLR3 and the macrophage marker CD68. The majority of cells expressing 
TLR3 did not stain for CD68, indicating that most synoviocytes expressing TLR3 were not 
macrophages but synovial fibroblasts (2). 
 
It is known that IL-6 exerts stimulatory effects on T- and B-cells, thus favoring chronic 
inflammatory responses, whereas matrix metalloproteinases (MMPs) have been closely linked 
to the progressive destruction of articular cartilage in rheumatoid joints. To analyze whether 
TLR signaling might contribute to the elevated IL-6, MMP1 and MMP3 levels in the 
rheumatoid joint, RASF were isolated from RA synovial tissues and stimulated with the 
TLR2, 3 and 4 ligands. 24h after stimulation cell culture supernatants were collected and the 
cells were lysed in order to isolate total RNA. In the cell culture supernatants IL-6 levels were 
measured by a commercially available enzyme linked immunosorbent assay (ELISA) set. 
Furthermore upregulation of MMP1 and MMP3 mRNA was determined by TaqMan Real-
time PCR. We found a strong upregulation of IL-6, MMP1 and MMP3 by all three TLR 
ligands, with a most marked upregulation reached by the TLR3 ligand poly(I-C) (2, 8). These 
results document a strong proinflammatory and joint destructing role of TLR signalling 
pathways in the pathogenesis of RA and identify TLRs as potential therapeutic targets. 
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2. Materials 
2.1 Synovial tissue preparation for immunohistochemistry 
1. Synovial tissue specimens were obtained during synovectomy or joint replacement 
surgery from patients with RA and OA, after informed consent has been obtained 
(Department of Orthopedic Surgery, Schulthess Clinic, Zurich, Switzerland). 
Embedded synovial tissues were maintained at -80°C until cryosectioned. 
2. Tissue-Tek® O.C.T™ Compound (TissueTek TT 4583; Sakura Finetech, Torrance, 
CA). Store at room temperature (RT). 
3. Freezing mold: Simport Biotubes (T100-20, Omnilab, Switzerland). Autoclave tubes 
before use.  
4. Superfrost™ Plus Slides (Menzel-Gläser, Braunschweig, Germany) 
 
2.2. Immunohistochemistry 
1. Fixation solution for frozen synovial tissue sections: pre-cooled Acetone (histological 
grade ≥99.5%). Pre-cool the amount of Acetone needed for the fixation (around 100 
ml of Acetone) at -20°C. (see Note 1) 
2. Blocking of endogenous peroxidase activity: 0.1% H2O2   (see Note 2 )  
3. Washing buffer (Tris buffered saline (TBS)): 100 mM Tris-HCl, pH 7.6, 150 mM 
NaCl 
4. Blocking buffer: 2% Fetal bovine serum (FBS) (Omnilab, Switzerland) in TBS 
5. Primary antibodies: Affinity-purified goat anti-human TLR-3 polyclonal IgGs (Cat. 
No. JM-3445-100,  MBL International, Woburn, MA), store at 4°C 
6. Negative control antibodies: ChromPure Goat IgG, whole molecule (Cat. No. 005-
000-003, Jackson ImmunoResearch Europe Ltd., Suffolk, UK), store at 4°C 
7. Dilution buffer for secondary antibodies: 2% bovine serum albumin (BSA, Sigma-
Aldrich), 5% human serum, in TBS (see Note 3) 
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8. Secondary antibodies: polyclonal rabbit anti-goat IgGs, biotinylated (Cat. No. E0466, 
DakoCytomation, Glostrup, Denmark), store at 4°C. 
9. Vectastain Elite ABC Kit for horse raddish peroxidase (HRP) (PK6100, Vector 
Laboratories, UK), store at 4°C. 
10. HRP substrate Chromogen: Aminoethylcarbazole (AEC) chromogen substrate 
(K3464,  DakoCytomation), store at 4°C. 
11. Macrophage specific primary antibodies: monoclonal mouse anti-human CD68 (Cat. 
No. M0718, DakoCytomation), store at 4°C. 
12. Negative control antibodies: Mouse IgG1 (Cat. No. X0931, DakoCytomation, 
Denmark), store at 4°C. 
13. Secondary Antibodies: polyclonal rabbit anti-mouse IgG, alkaline phosphatase (AP)-
conjugated (DakoCytomation), store at 4°C. 
14. AP substrate Chromogen: Fast Blue BB reagent: mix naphthol-AS-MX phosphate 
dissolved in N,N-dimethylformamide immediately before use with Fast Blue BB 
dissolved in TBS, pH 8.5 (Sigma-Aldrich, Switzerland). 
15. Nuclear counterstain: Hematoxylin solution according to Mayer (Cat. No. 51275, 
Sigma-Aldrich). 
16. Mounting medium: Glycine Gelatine 
 
2.3. Cell culture 
1. Protease for the dissociation of synovial tissues to release individual cells: Dispase II 
(17105-041, Gibco, Basel, Switzerland) 
2. Fetal bovine serum (FBS) (Omnilab, Switzerland), heat inactivate FBS for 30min at 
56°C. Store heat inactivated FBS at -20°C. 
3. Cell culture medium: Dulbecco’s Modified Eagle’s Medium / F-12 supplemented with 
10% heat inactivated FBS, 50 IU/ML Penicillin-Streptomycin, 2 mM L-Glutamin, 10 
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mM Hepes and 2% Fungizone® Antimycotic (all from Gibco). Sterile filtration 
through 0.22 µm Syringe Filter (TPP, St. Louis, MO) before storage at 4°C. (see Note 
4) 
4. Trypsin/EDTA - 0.05 % Trypsin, 0.53 mM EDTA•4Na (Cat. No.25300-054, Gibco), 
store at -20°C. 
5. Phosphate buffered saline (PBS): 136.9 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 KH2PO4 (adjust to pH7.4 with HCl if necessary). PBS is autoclaved before storage 
at room temperature. 
 
2.4. TLR ligands for in vitro stimulation of RASF 
1. Synthetic bacterial lipoprotein (bLP) as TLR2 ligand: N-Palmitoyl-S-[2,3-
bis(palmitoyloxy)-(2RS)-propyl]-[R]-Cys-[S]-Serl-[S]-Lys (4) trihydrochloride 
(Pam3CSK4, Invivogen, San Diego, CA). Dissolve bLP to a concentration of 1 mg/ml 
in endotoxin free dH2O and store in single use aliquots at -20°C. 
2. Synthetic dsRNA as TLR3 ligand: Polyriboinosinic polyribocytidylic acid (poly(I-C), 
Invivogen, San Diego, CA). Dissolve poly(I-C) to a concentration of 2.5 mg/ml in 
endotoxin free dH2O and store in single use aliquots at -20°C. 
3. Lipopolysaccharide (LPS) as TLR 4 ligand: Escherichia coli derived (List Biological 
Laboratories, Campbell, CA). Dissolve LPS to a concentration of 100 μg/ml in dH2O 
and store aliquots at -20°C. 
 
2.5. Taqman Real-time polymerase chain reaction (PCR) 
1. RNA isolation: Total RNA from cultured RASF is isolated with the RNeasy Mini kit 
(Qiagen, Basel, Switzerland), including treatment with RNase-free DNase (Qiagen). 
2. Reverse transcription reagents from Applied Biosystems, Rotkreuz, Switzerland: 
MultiScribe™ Reverse Transcriptase (RT) (50U/µl), random hexamers (50uM), dNTP 
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(10 mM solution of 2.5 mM each of dATP, dCTP, dGTP and dTTP), 10x PCR Buffer 
II (contains no MgCl2), RNase inhibitor (20U/µl). Store all reagents at -20°C. 
3. Primer/Probe sequences used for real-time PCR from Microsynth, Balgach, 
Switzerland: MMP1 forward primer: 5’-tgt-gga-cca-tgc-cat-tga-ga-3’; MMP1 reverse 
primer: 5’-tct-gct-tga-ccc-tca-gag-acc-3’, FAM/TAMRA labeled MMP1 specific 
probe: 5’-agc-ctt-caa-act-ctg-gag-taa-tgt-cac-acc-3’. MMP3 forward primer: 5’-ggg-
cca-tca-gag-gaa-atg-ag -3’; MMP3 reverse primer: 5’-cac-ggt-tgg-agg-gaa-acc-ta -3’, 
FAM/TAMRA labeled MMP3 specific probe: 5’-agc-tgg-ata-ccc-aag-agg-cat-cca-cac 
-3’. Dissolve stock primer solutions to a working concentration of 11.25μM and the 
probe sequences to a working concentration of 5nM in dH2O before storage at -20°C. 
4. Eukaryotic 18S rRNA Endogenous Control: 18S VIC/TAMRA labeled Probe, Primer 
Limited (Applied Biosystems), store at -20°C. 
5. qPCR Master Mix: 2x reaction buffer containing dNTP/dUTP, HotGoldStar, MgCl2 (5 
mM final concentration), UNG, stabilizers and ROX passive reference (Eurogentech, 
Genève, Switzerland), store at -20°C. 
6. MicroAmp Optical 96-well Reaction Plate and corresponding MicroAmp Optical Caps 
(Applied Biosystems) 
 
2.6. Enzyme linked immunsorbent assay (ELISA) for IL-6 
1. BD OptEIA™ Human IL-6 ELISA Set: Capture antibody: Anti-human IL-6 (store at 
4°C); Detection antibody: Biotinylated anti-human IL-6; Enzyme reagent (store at 
4°C): Avidin-horseradish peroxidase conjugate (store at 4°C); Standard: Recombinant 
human IL-6 (store in single use aliquots at -80°C). 
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3. Methods: 
To analyze whether TLRs might play a role in the pathogenesis of RA the first step was to 
investigate whether TLRs are present in the rheumatoid synovium. Furthermore, TLR 
expression was compared between RA and non-inflammatory OA patients, in order to study 
the pathogenic relevance of TLR expression in RA. To obtain reliable results it is essential 
that tissue specimens obtained after surgery are immediately embedded in O.C.T compound 
and snap frozen in liquid nitrogen. 
 
3.1. Preparation of fresh frozen tissue sections 
1. O.C.T. embedding: Label plastic tissue mold with proper tissue identification and 
prepare the mold with a small layer of O.C.T. Immediately after surgery place the 
tissue in desired orientation and completely fill the mold with O.C.T. Note that the 
bottom of the mold is where cutting will begin. The O.C.T compound will begin to 
turn white as it freezes. Freeze tissue by placing mold on the surface of liquid nitrogen 
until 70-80% of the block turns white. Then, immerge the embedded tissue into liquid 
nitrogen for at least 5 min. Retrieve the mold from liquid nitrogen and store the 
embedded tissue at -80C or move directly to cryostat. 
2. Sectioning: Transfer the embedded tissue on dry ice to cryostat and let it equilibrate 5 
min to cryostat temperature (-20C). Sections are usually obtained when the 
temperature is -18 to -20C. The O.C.T. embedded tissue is fixed to chuck with 
O.C.T. media. Cut 8 m sections and mount sections on positivly charged slides. Let 
sections air dry for 30 min at room temperature. After drying, slides are stored at -





3.2. Immunohistochemical staining on frozen synovial tissue sections 
3.2.1. Immunohistochemical staining for TLR3 
1. Fixation: Let the tissue sections air dry for 30 min. Subsequently place the sections in 
a coplin jar (see Note 6) with -20°C pre-cooled 100% Acetone for 15 min. After 
fixation, the tissue sections have to be air dried for at least 60 min. 
2. Rehydrate tissue sections with 2 washes of dH2O (see Note 7).  
3. Block endogenous peroxidase activity with 0.1% H2O2 for 10 min. Rinse the sections 
once with dH2O and once for 5 min with TBS (washing buffer).  
4. Incubate sections in blocking buffer (TBS, 2% FBS) for 30 min at room temperature 
to reduce non- specific binding of antibodies. Perform the incubation in a sealed 
humidity chamber to prevent air-drying of the tissue sections. 
5. Gently shake off excess blocking buffer and cover sections with primary antibodies or 
negative control antibodies diluted in blocking buffer (5 μg/ml anti-human TLR3 
antibodies or goat IgGs, respectively, diluted in TBS, 2% FBS). Place the sections in 
the humidity chamber and incubate either at room temperature for 1 hour or overnight 
at 4°C. (see Note 8) 
6. Rinse sections 3 times for 5 min in TBS, shaking gently. 
7. Gently remove excess TBS and cover sections with 1:2000 diluted biotinylated rabbit 
anti goat antibodies in dilution buffer (TBS, 2%BSA, 5% human serum) for 30 min at 
room temperature in the humidity chamber. The addition of human serum decreases 
unspecific background on human tissue sections 
8. During the incubation period prepare Vectastain ABC reagent, according to the 
manufacturer’s instruction. (see Note 9). 
9. After incubation rinse tissue sections 3 times for 5 min in TBS, shaking gently 
10. Gently remove excess TBS and cover sections with Vecstatin ABC reagent (see 
3.2.1.8). Incubate tissue sections for 30 min in the humidity chamber. 
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11. Rinse sections 3 times for 5 min in TBS, shaking gently. 
12. Apply AEC substrate-chromogen solution and incubate 2-5 min or until desired color 
intensity has developed.  
13. Rinse sections two times for 5 min with dH2O, shaking gently. 
14. Counterstain the sections for 5-10 seconds with the hematoxylin counterstaining 
solution. 
15. Rinse the slides under gently running tap water for 5 min (avoid a direct jet which may 
wash off or loosen the section).  
16. Mount the sections using aqueous mounting medium such as glycerol gelatine. 
Coverslip may be sealed with clear nail polish. (see Note 10) 
An example of the results produced is shown in Figure 1. 
 
3.2.2. Double staining for TLR3 and CD68 
Because TLR3 and CD68 specific antibodies are derived from different host species, the 
simultaneous staining method can be applied. Simultaneous staining is less time-consuming 
than the sequential method, since primary and secondary antibodies can be mixed together in 
two incubation steps.  
1. Follow  steps 1-4 according to the protocol 3.2.1: Fixation (1) and rehydration (2) of 
the tissue sections,  followed by blocking the peroxidase activity (3) and blocking of 
unspecific binding (4). 
2. Gently shake off excess blocking buffer and cover sections with TLR3 and CD68  
specific antibodies (5 μg/ml anti-human TLR3 antibodies /  5 μg/ml mouse anti-human 
CD68 antibodies) or corresponding negative control antibodies (5 μg/ml goat IgGs / 5 
μg/ml mouse IgG1)  diluted in blocking buffer (TBS, 2% FBS). Replace the sections 
in the humidity chamber and incubate either at room temperature for 1 hour or 
overnight at 4°C. 
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3. Rinse sections 3 times for 5 min in TBS, shaking gently. 
4. Gently remove excess TBS and cover sections with biotinylated rabbit anti-goat 
(dilution 1:4000) and AP labeled rabbit anti mouse (dilution 1:500) antibodies in the 
dilution buffer (TBS, 2% BSA, 5% human serum). Incubate tissue sections for 30 min 
at room temperature in the humidity chamber. (see Note 11) 
5. During incubation period prepare Vectastatin ABC reagent (as per kit instruction). 
After incubation rinse tissue sections 3 times for 5 min in TBS, shaking gently. 
6. Gently remove excess TBS and cover sections with Vectastatin ABC reagent (see 
3.2.2.5). Incubate tissue sections for 30 min in the humidity chamber. 
7. Rinse sections 3 times for 5 min in TBS, shaking gently. 
8. Apply AEC substrate-chromogen solution and incubate 2-5 min or until desired color 
intensity has developed (TLR3 positive cells appear in red). 
9. Rinse sections twice for 5 min with dH2O, shaking gently 
10. Apply AP substrate-chromogen solution and incubate for 1-5 min or until desired 
color intensitiy is developed (CD68 positive cells appear in blue). 
11. Rinse sections twice for 5 min with dH2O, shaking gently. 
12. Coverslip the sections using aqueous mounting medium such as glycerol gelatine. (see 
Note 12) An example of the results produced is shown in Figure 2. 
 
3.3. Cell culture: Isolation of primary synovial fibroblasts 
1. Mince fresh RA synovial tissue in a Petri Dish. During mincing, add 2-5 ml cell 
culture medium so that the synovial tissue does not dry out. 
2. Transfer minced tissue into a 100 ml glass bottle and add 50 ml of Dispase solution 
(1.5 mg/ml Dispase II in cell culture medium). Stir minced synovial tissue with a 
magnetic stirrer for 90 min at 37°C.  
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3. Transfer Dispase solution containing the detached cells into 50 ml centrifuge tubes. 
After centrifugation at 400g for 10 min, discard the supernatant and resuspend the 
cells in 5 ml cell culture medium.  
4. Incubate the synovial cells in cell culture medium (total volume of 15 ml) in a 75 cm2 
cell culture flask for 24h. After that, change cell culture medium to remove non-
adherent cells. When the adherent cells reach a confluency of approximately 80%, 
usually after 3-7 days of incubation, cells can be further passaged.  
5. Passage of adherent RASF:  Aspirate off the cell culture medium and discard. Add 
PBS carefully to the flask (10 ml/75 cm2 flask), without disturbing the monolayer. 
Rinse the monolayer by gently rocking the flask. Remove the PBS and discard (see 
Note 13).  Add trypsin/EDTA (3 ml/75 cm2 flask) and rock the flask to ensure that the 
entire monolayer is covered with the trypsin solution. Return the culture flask to the 
incubator and leave for 5-10 min until the cells are round shaped and begin to detach. 
The side of the flasks may be gently tapped to release any remaining attached cells. 
Then inactivate the trypsin by adding cell culture medium containing FBS (10 ml/75 
cm2 flask) and pipet the cells up and down until the cells are dispersed into a single 
cell suspension. Collect the cell suspension in a 15 ml centrifuge tube and pellet the 
cells by centrifugation at 400g for 10 min.  Aspirate off the supernatant and resuspend 
the pellet in 10 ml cell culture medium.  To split the cells in a ratio of 1:2, transfer 5 
ml of the cell-suspension to a new labeled flask containing 5 ml pre-warmed medium. 
Incubate the cultures until the cells are approaching confluence (7-14 days) and then 
repeat the process. After 4 passages the primary cell cultures contain fibroblast-like 
cells (RASF) only.  
 
3.4. Stimulation of RASF with TLR ligands 
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1. Detach RASF with trypsin as described above (see 3.3.5), and pellet cells at 400g for 
10 min. Subsequently resuspend the cell pellet in 1 ml cell culture medium and count 
cells with the use of the Neubauer-counting chamber. Calculate the total cell number 
and dilute the cells to a final concentration of 6 x 104 RASF/ml. (see Note 14) 
2. Place 2 ml of cell suspension per well into 4 wells of a 6-well plate (1.2 x 105 
RASF/well). Make sure, that RASF are evenly distributed over the well and after that 
let the cells settle overnight in the incubator. 
3. The next day dilute TLR ligands in pre-warmed cell culture medium to obtain the 
appropriate working concentrations. For 300 ng/ml bLP working solution, dilute 3 µl 
bLP stock solution in 10ml culture medium, for 10 μg/ml poly(I-C) working solution, 
dilute 40µl poly(I-C) stock solution in 10 ml medium and for 100 ng/ml LPS working 
solution dilute 10 µl LPS stock solution in 10 ml medium. 
4. Subsequently stimulate RASF with TLR ligands: Remove 6-well plate from the 
incubator, aspirate off culture medium and wash the RASF monolayer gently with 
PBS. Pipet off PBS and add 2 ml cell culture medium as non stimulated control to 1 
well of the 6-well plate. For TLR2 stimulation add 2 ml bLP working solution, for 
TLR3 stimulation 2 ml poly(I-C) working solution and for TLR4 stimulation 2 ml 
LPS working solution.  
5. Incubate nonstimulated and TLR ligand stimulated RASF for 24h. 
 
3.5. Sample preparation: Collection of culture supernatants and cell lysis for RNA 
isolation  
1. 24h after TLR ligand stimulation remove the 6-well plate from the incubator, and 
transfer cell culture supernatants of TLR ligand and unstimulated RASF in 4 labeled 
Eppendorf-tubes, correspondingly. Remove cell debris in cell culture supernatants by 
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centrifugation at 1000g for 2 min and transfer supernatants in fresh tubes 
correspondingly. Store cell culture supernatants at -20°C. (see Note 15) 
2. After rinsing the RASF gently with 2 ml PBS per well, lyse the cells by adding 350 µl 
RLT buffer per well for subsequent total RNA isolation. Mix thoroughly and transfer 
the cell lysates of the test samples  to 4 labeled RNase free Eppendorf tubes, 
correspondingly. Cell lysates can be stored at -20°C until proceeding to RNA 
isolation. 
 
3.6. TaqMan Real-time PCR 
1. Isolate total RNA according to the manufacturers instructions (RNeasy Mini Kit), 
including treatment with RNase-free DNase. (see Note 16) 
2. Reverse transcriptase (RT): Total RNA is reverse transcribed into cDNA with random 
hexamer primers to transcribe all RNA (mRNA, rRNA, tRNA). Prepare RT reaction 
mix for the 4 total RNA test samples by pipetting 8 µl 10X RT buffer, 17.6 µl MgCl2, 
16 µl dNTP, 4 µl random hexamer, 1.6 µl RNase Inhibitor and 2 µl MultiScribe RT in 
a RNase free Eppendorf tube (20µl reaction per sample). Label four 0.2-ml MicroAmp 
reaction tubes for the four total RNA test samples. Pipette 12.3µl of the RT reaction 
mix (1X PCR Buffer, 5.5 mM MgCl2, 2 mM dNTP, 0.4 U/ml RNase inhibitor, 
1.25U/ml MultiScribe RT) to each MicroAmp reaction tube. Transfer 300-500ng total 
RNA to the corresponding reaction tube in a volume of 7.7µl (fill up with DEPC 
water, if necessary, total volume 20μl per reaction). Cap the reaction tubes and tap 
gently to mix the reactions. Centrifuge the tubes briefly to force the solution to the 
bottom and to eliminate air bubbles from the mixture. Transfer the tubes to the thermal 
cycler block and perform RT: 10 min at 25°C, 30 min at 48°C, 5 min at 95°C, hold at 
4°C. 
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3. TaqMan Real-time PCR: Prepare 18S, MMP1 and MMP3 TaqMan Reaction mix  for 
the 4 cDNA test samples (25 µl reaction per sample per well, in duplicates). For the 
18S TaqMan Reaction mix, pipette 100 µl qPCR Master Mix, 10 µl 18S primer/probe 
and 82 µl dH2O in a Eppendorf tube. For the MMP1 and MMP3 TaqMan Reaction 
mix, pipette 100µl qPCR Master Mix, 8 µl probe, 16 µl forward primer, 16 µl reverse 
primer and 52µl dH2O in an Eppendorf tube. Vortex the TaqMan reaction mix briefly 
and pipette 24µl of the reaction mix per well of a MicroAmp 96-well reaction plate (8 
wells per TaqMan Reaction mix). Take the 4 cDNA test samples and pipette 1µl 
cDNA per well to the according reaction mix (in duplicates). Cap and centrifuge the 
reaction plate briefly to force the solution to the bottom and to eliminate air bubbles 
from the mixture. Transfer the reaction plate to the ABI Prism 7700 Sequence 
Detection system (Applied Biosystems). (see Note 17) 
4. Use the endogenous control 18S cDNA  to normalize the results, according to the 
comparative threshold cycle (Ct) method for relative quantification, as described by 
the manufacturer. Calculate the differences in Ct values ( Ct) between the sample and 
the 18S cDNA. Then calculate relative expression levels according to the following 
formula: Ct = Ct (stimulated sample) - Ct (unstimulated sample). The value to 
plot relative expression is calculated according to the expression: 2- Ct. 
An example of the results produced is shown in Figure 3. 
 
3.6. IL-6 ELISA 
To determine the levels of IL-6 protein in the cell supernatants by ELISA, use the OptEIA 
human IL-6 set according to the manufacturer's instructions. Briefly, coat IL-6 capture 
antibodies overnight on 96-well immunosorbant plates. Block plates with PBS/10% FBS. Add 
diluted cell supernatants (1:50 -1:500) and incubate for 1 hour. Detect IL-6 protein with a 
complex of biotinylated anti-IL-6 and avidin-horseradish peroxidase conjugate and use 
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tetramethylbenzidine hydrogen peroxide as substrate. Measure absorption at 450 nm. An 
example of the results produced by analysis of the data using Revelation software, version 





1. Pre-cooled acetone can be reused several times for the fixation of tissue sections. 
2. Unless stated otherwise, all solutions should be prepared in deionized water (dH2O). 
3. Human serum was collected following Ficoll gradient centrifugation of heparinized 
blood. 
4. Cell culture medium has to be pre-warmed at 37°C before use. 
5. Alternatively, tissue sections may be fixed in –20C pre-cooled acetone for 10 min, 
dried, and then stored at room temperature. 
6. A coplin jar is a moulded glass jar with drop-on lid and integral large diameter base. 
The jar has grooves to accept 76 x 26mm microscope slides vertically. 
7. All rinsing steps are performed in Coplin jars. Always use large amounts of wash 
buffer, especially after antibody incubations, to reduce background. 
8. For economy, use only 100-150µl of diluted antibodies per sample.  
9. Streptavidin Avidin complex formation needs at least 30 min. 
10. When using AEC substrate, do not use alcohol-containing solutions for counter-
staining (e.g., Harris' hematoxylin, acid alcohol), since the AEC stain formed by this 
method is soluble in organic solvents. The slide must not be dehydrated, brought back 
to toluene (or xylene), or mounted in toluene-containing mountants. AEC is also 
susceptible to further oxidation when exposed to light and thus it will fade over time. 
Dark storage and brief light viewing are recommended.  
11. Generally, for the simultaneous staining method, it is advantageous to use secondary 
antibodies raised in the same host in order to prevent any unexpected inter-species 
cross reactivity.  
12. Fast Blue substrate, similar to AEC substrate, is soluble in alcoholic and other organic 
solvents, so aqueous mounting media must be used. 
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13. Serum contains trypsin inhibitors. Thus it is important to remove traces of serum in 
this step.  
14. In order to work with a homogenous synovial fibroblast cell culture, use RASF that 
were passaged 4-6 times. It has been shown that over 6 passages significant changes in 
gene expression might occur. 
15. When multiple experiments will be performed with the same cell culture supernatants, 
aliquot  the samples to avoid freeze/thaw cycles. 
16. TaqMan Real-time PCR analysis is sensitive to very small amounts of DNA, therefore 
on-column DNase digestion is necessary to optain reliable results. 
17.  For economy, only 12.5µl instead of 25µl TaqMan reactions per sample can be used. 
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Figure 1. Detection of TLR3 protein in synovial tissues  from patients with RA and 
osteoarthritis (OA).  
Tissue sections of patients with RA (A-C) and OA (D-F) were stained with anti-TLR3 
antibodies (A, B, D, E) or with the respective isotype control antibodies (C, F). TLR3 protein 
presents as red color. In A-F, nuclei were stained with hematoxylin. In RA synovial tissues 
TLR3 is abundantly present with a pronounced expression in the synovial lining layer. In OA 
synovial tissue TLR3 expression is markedly lower in comparison to RA.  
 





Figure 2: Detection of TLR3 and CD68 double positive cells  
RA synovial tissue sections were double stained for TLR3 and CD68 or with corresponding 
isotype antibodies, respectively. TLR3 positive cells appear in red, CD68 positive cells in 
dark blue. Most TLR3 positive cells are not positive for CD68. Since the synovial lining layer 
consist of macrophages and activated synovial fibroblasts the results indicate that RASF are 
the major cells in the synovial lining expressing TLR3. 
 







































































Figure 3: MMP1 and MMP3 mRNA upregulation in RASF following stimulation with 
TLR 2, 3 and 4 ligands 
RASF derived from 5 individual RA patients were stimulated with the TLR2,3 and 4 ligands 
bLP, poly(I-C) and LPS for 24h. MMP1 and MMP3 mRNA expression was significantly 
































Figure 4: IL-6 production by RASF after TLR ligand stimulation 
RASF derived from individual RA patients (n=7) were untreated or stimulated with the TLR2 
ligand bLP, the TLR3 ligand poly(I-C) or with the TLR4 ligand LPS. RASF treated with TLR 
ligands upregulated the IL-6 production significantly compared to untreated cultures. The 
most marked upregulation was found after stimulation with poly(I-C). 
 
